Rehospitalization risk with second-generation and depot antipsychotics

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Hospital readmissions negatively impact outcomes for schizophrenia patients.
• Second-generation antipsychotics (SGAs) offer better tolerability for long-term schizophrenia treatment.
• Long-term outcomes of SGAs compared to depot antipsychotics require further investigation.

Purpose of the Study:

• To evaluate and compare the 1-year readmission risk of patients with schizophrenia treated with clozapine, risperidone, or olanzapine versus those treated with fluphenazine decanoate or haloperidol decanoate.

Main Methods:

• Retrospective cohort study of patients discharged on specific antipsychotics from Maryland state facilities (1997-1997).
• Comparison of 1-year readmission rates using Kaplan-Meier survival analysis and Log Rank tests with Holm's adjustment.
• Analysis included clozapine (N=41), risperidone (N=149), olanzapine (N=103), fluphenazine decanoate (N=59), and haloperidol decanoate (N=59).

Main Results:

• One-year readmission risks: clozapine (10%), risperidone (12%), olanzapine (13%), fluphenazine decanoate (21%), haloperidol decanoate (35%).
• SGAs showed significantly lower readmission risk than haloperidol decanoate.
• No significant difference in readmission risk was found between SGAs and fluphenazine decanoate.
• Demographic and clinical variables did not predict readmission across medication groups.

Conclusions:

• Second-generation antipsychotics (SGAs) demonstrate comparable or superior 1-year readmission risk profiles compared to traditional depot antipsychotics in schizophrenia.
• SGAs may offer improved long-term prognoses and patient outcomes, potentially reducing hospitalizations.
• These findings support the use of SGAs for managing schizophrenia and preventing relapse.